

Iowa Department of Human Services

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

Request for Prior Authorization MULTIPLE SCLEROSIS AGENTS-ORAL

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name		DOB		
Patient address					
Provider NPI	Prescriber name		Phone		
Prescriber address			Fax		
Pharmacy name	Address		Phone		
Prescriber must complete all informa	ation above. It must be legible	correct, and complete	or form will be returned.		
Pharmacy NPI	Pharmacy fax	NDC			
For patients initiating therapy with a preferred oral medication, a manual prior authorization is not required if a preferred injectable interferon or non-interferon is found in the member's pharmacy claims history in the previous 12 months. If a preferred injectable agent is not found in the member's pharmacy claims, documentation of the following must be provided: 1) A diagnosis of relapsing forms of multiple sclerosis, and 2) Patient meets the FDA approved age; and 3) A previous trial and therapy failure with a preferred interferon or non-interferon used to treat multiple sclerosis; and 4) Requests for a non-preferred oral multiple sclerosis agent must document a previous trial and therapy failure with a preferred oral multiple sclerosis agent. The required trial may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated. Preferred Aubagio Gilenya Tecfidera Strength Dosage Instructions Quantity Days Supply					
Diagnosis:					
Treatment failure with interfer	on or non-interferon:				
Trial Drug Name & Dose:		_Trial Dates:			
Reason for failure:					
Possible drug interactions/conflicting drug therapies:					
For patients initiating therapy with fingolimod (Gilenya):					
	attack, decompensated hear		farction, unstable angina, stroke, alization, or Class III/IV heart		

Iowa Department of Human Services

Request for Prior Authorization MULTIPLE SCLEROSIS AGENTS-ORAL

(PLEASE PRINT - ACCURACY IS IMPORTANT)

•	Patient has a history or presence of Mobitz Type II 2 nd degree syndrome: Yes No If yes, patient has a pace		or sick sinus			
•	Patient has a baseline QTc interval ≥ 500ms:	□ No				
•	Patient is being treated with Class la or Class III anti-arrhythmic	c drugs:	☐ No			
For patients initiating therapy with teriflunomide (Aubagio):						
•	Patient has severe hepatic impairment: Yes No					
 Patient has a negative pregnancy test if female of childbearing age: Yes						
•	If female of childbearing age, specify plan for contraception:					
•	Patient is taking leflunomide:					
For patients initiating therapy with dimethyl fumarate (Tecfidera):						
 Patient has a low lymphocyte count documented by a recent (within 6 months) CBC: Yes No Lab Date: 						
For renewal, documentation of an updated CBC: Lab date:						
Attach lab results and other documentation as necessary.						
Prescriber signa	ature (Must match prescriber listed above.)	Date of submission				

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

470-5060 (Rev. 1/19) Page 2 of 2